A Dual-Action NKT Immunotherapy Redefining Cancer Treatment
Niktoraal represents a new frontier in cellular immunotherapy, merging the precision of T cells with the innate cytotoxic power of Natural Killer (NK) cells. Developed from patient-derived peripheral blood and expanded through specialized cytokine-based culture method, Niktoraal is a next-generation NKT cell therapy designed to unleash the body’s full immune potential against cancer.
Through this dual-functionality approach, Niktoraal targets malignant cells with both innate and adaptive immune mechanisms, paving the way for more powerful and sustained anti-tumor response.
In vitro expansion of NK cells from PB-MNCs. During NKT cell expansion, the cellular morphology changed from single cells to colonies, then large cellular clusters (10x magnification, scale bar =100µm), (20x magnification, scale bar =50µm).
Niktoraal is currently under research and development for preclinical models.
Immunophenotypic characterization of NKT cells during in vitro expansion.
(A) Flow cytometry analysis of representative NK (CD56+/16+/CD3-), NKT (CD56+/16+/CD3+), and T (CD3+) cells at different time points of culture (0,7,14 and 21)